peter Attia Steps Down From David Protein Amidst Epstein Document Release
The world of longevity and preventative health is navigating a period of scrutiny as Dr. Peter Attia, a leading voice in the field, has stepped down from his position as Chief Science Officer at david Protein, a popular nutrition bar company.This declaration, made by David Protein founder Peter Rahal on X (formerly Twitter), follows the surfacing of Dr. Attia’s name in over 1,700 documents released as part of a court-ordered disclosure related to convicted sex offender Jeffrey Epstein.
dr. Attia gained widespread recognition through his bestselling book, “Outlive: the Science and Art of Longevity,” and his long-running podcast, where he explores cutting-edge strategies for health optimization. He had recently expanded his media presence wiht a new contributor role at CBS, further solidifying his influence. His involvement with David Protein extended beyond a scientific advisory role; he was also an early investor in the company, which has experienced rapid growth since launching its protein-rich, low-sugar bars in 2024 and securing $75 million in Series A funding.
The released documents, reported on by The New York Times, have prompted Dr. Attia to address the situation publicly. In a detailed post on X, he acknowledged being “ashamed” of certain content within the emails, while firmly maintaining that he was not involved in any criminal activity and did not visit Epstein’s island or travel on his private plane. He further explained the nature of his association with Epstein and the reasons for its continuation despite the 2008 conviction.
The fallout from this association appears to be extending beyond David Protein. Biograph, a healthcare testing and longevity startup co-founded by Dr. Attia, is also distancing itself from the physician. References to Dr. Attia as a co-founder have been removed from the company’s website, with some pages returning error messages, indicating a intentional effort to disassociate.
Biograph, which launched in 2025, offers premium preventative health services to a subscriber base willing to pay between $7,500 and $15,000 annually. The company had previously highlighted Dr. Attia’s involvement in press releases and website materials, showcasing his expertise as a core component of its offering. Investors in Biograph include prominent venture capital firms like Vy Capital and Human Capital, and also angel investors like Balaji Srinivasan.
This situation raises complex questions about the intersection of personal associations and professional reputation, particularly within the rapidly evolving field of longevity and preventative health. The coming weeks will likely reveal the full extent of the repercussions for both Dr. Attia and the companies with which he is affiliated.